He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

He discusses Biohaven, Xenon, Biogen, and Sarepta.

His widely read report shows the data behind what venture deals got done last year, who are the venture investors that have been most active in deploying capital, the fundraising and IPO environment, and which technologies and indications are seeing the most investor interest. DOWNLOAD THE FREE REPORT #sponsored

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences Chapters BridgeBio - 1:08 Cytokinetics - 12:14 Vaxcyte - 17:40 Biogen - 23:43 Arcus Biosciences - 26:48

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026. Chapters Wegovy in a pill - 1:04 Lilly’s pill orforglipron - 9:14 Structure’s pill aleniglipron - 13:13 Lilly’s retatrutide - 16:33 Amylins (Zealand and others) - 19:47 Corbus’ CB1 inverse agonist – 24:53 Viking - 28:02

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects. Chapters Intro - 0:59 Maintenance - 3:54 Commercial prospects - 18:16 Crohn's - 21:43 Buyout prospects - 27:03 How did Wall Street analysts miss this? - 41:31

He mentions Terns, Corvus, Insmed, Corbus, Axsome, Neumora, Eyepoint, and Amylyx. Chapters His general take on biotech - 1:28 Terns - 7:25 Corvus - 12:49 Insmed - 16:26 Corbus - 20:44 Others with upcoming catalysts - 26:44

They describe an uptick in the mood of the industry as well as hiring. Plus, helping companies fulfill their goal to have an employee base that is back working in the office. Coverage brought to you by

Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment. Coverage brought to you by

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by

Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific. Coverage brought to you by

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by

He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka. Coverage brought to you by

He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by

He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by

She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.